Asundexian Associated with an Impressive 26% Reduction in Recurrent Stroke Without Increased Bleeding. The OCEANIC-STROKE trial
Asundexian is a direct, potent small molecule inhibitor of Factor XIa (FXIa).…
ACST-2: Largest trial to date comparing carotid artery stenting to carotid endarterectomy finds no difference in disabling stroke at 5 years.
Key Points: Carotid artery stenting and carotid endarterectomy have both been employed…